Chartrand S A, Scribner R K, Weber A H, Welch D F, Marks M I
Antimicrob Agents Chemother. 1983 May;23(5):658-63. doi: 10.1128/AAC.23.5.658.
We tested CI-919 (AT-2266), a nalidixic acid analog, against 555 gram-positive and gram-negative bacteria, using microbroth or agar dilution methods. The activity of CI-919 was compared with those of cephalosporins, tobramycin, ticarcillin, dicloxacillin, rifampin, chloramphenicol, ampicillin, and trimethoprimsulfamethoxazole. The minimal inhibitory concentrations of CI-919 for 90% of isolates were (in micrograms per milliliter): Pseudomonas spp. (including Pseudomonas aeruginosa), 4.0; Enterobacteriaceae, 0.5; Staphylococcus spp., 2.0; Haemophilus influenzae, 0.12; Campylobacter jejuni, 0.12; and enterococci, 16. The minimal inhibitory concentrations of CI-919 for 90% of 82 tobramycin-resistant, gram-negative strains was 4.0 micrograms/ml. CI-919 was bactericidal for most isolates, showing no cross-resistance with unrelated antimicrobial agents, and was stable for 11 weeks at temperatures ranging from 22 to -70 degrees C. Inoculum size and media pH had little effect on the antibacterial activity of CI-919 for nine strains tested. CI-919 may be useful as an oral antibiotic for the treatment of infections due to diverse bacteria, including P. aeruginosa.
我们使用微量肉汤或琼脂稀释法，对萘啶酸类似物CI-919（AT-2266）针对555株革兰氏阳性和革兰氏阴性细菌进行了测试。将CI-919的活性与头孢菌素、妥布霉素、替卡西林、双氯西林、利福平、氯霉素、氨苄西林和甲氧苄啶磺胺甲恶唑的活性进行了比较。CI-919对90%分离株的最低抑菌浓度（以微克/毫升计）为：假单胞菌属（包括铜绿假单胞菌），4.0；肠杆菌科，0.5；葡萄球菌属，2.0；流感嗜血杆菌，0.12；空肠弯曲菌，0.12；肠球菌，16。CI-919对82株耐妥布霉素革兰氏阴性菌株中90%的最低抑菌浓度为4.0微克/毫升。CI-919对大多数分离株具有杀菌作用，与不相关抗菌药物无交叉耐药性，并且在22至 -70摄氏度的温度范围内可稳定11周。接种量和培养基pH值对测试的9株菌株的CI-919抗菌活性影响很小。CI-919可用作口服抗生素，用于治疗包括铜绿假单胞菌在内的多种细菌引起的感染。
